Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
Turn Therapeutics, Inc. (
NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the treatment of atopic dermatitis.
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
Turn Therapeutics, Inc. (
NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program.
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis.
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the effects of its lead program, GX-03, in an IL-36–associated inflammatory environment.
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City as follows:
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced the appointment of Stephen M. Hahn, M.D., former Commissioner of the U.S. Food and Drug Administration (FDA), to oversee the clinical and regulatory strategy for GX-03, the Company’s investigational topical therapy currently in a Phase 2 clinical trial for moderate-to-severe atopic dermatitis (eczema).
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026, and provided corporate updates.
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results for the year ended December 31, 2025, and provided corporate updates.
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, for up to $25 million. The facility includes an initial $7 million tranche funded at closing, with up to an additional $18 million available upon achievement of clinical and corporate milestones.
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today announced the appointment of Robert Redfield, M.D., as Senior Advisor of Health Policy and Regulatory Affairs. In this role, Dr. Redfield will provide strategic guidance on clinical development, public health implications, and regulatory positioning of the company’s lead investigational therapy, GX-03, which is currently in Phase 2 clinical trials.
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief Executive Officer, will present at the 46th Annual TD Cowen Healthcare Conference and the 36th Annual Oppenheimer Healthcare Life Sciences Conference.
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic and infectious diseases, today announced corporate, financial, and pipeline updates in advance of its participation at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco. Throughout the conference, Turn Therapeutics will participate in investor and partner meetings to discuss the Company's clinical progress, expanding pipeline, capital position, and anticipated 2026 milestones.
Turn Therapeutics Appoints Martin Dewhurst to its Board of DirectorsMr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online MagazineTurn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate CommunicationsLOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced the appointment of Andrew Scott as Vice President of Corporate Communications. In this new role, Mr. Scott will oversee investor relations, capital markets strategy, and corporate communications, while supporting the Company’s licensing and partnership initiatives.
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor MedlineAgreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunities
Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic MilestonesCompany to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy
Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025LOS ANGELES, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) today announced the launch of a broad communications initiative, featuring a recurring webinar series for shareholders and a forthcoming Founder Blog authored by patient-turned-founder and CEO, Bradley Burnam.
Turn Therapeutics Appoints Dr. Kent Kester to Board of DirectorsSeasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research
Turn Therapeutics Appoints Arthur Golden to Board of DirectorsVeteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs
